These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Is Elan a turnaround? Jacobs T Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557 [No Abstract] [Full Text] [Related]
13. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006. Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863 [TBL] [Abstract][Full Text] [Related]
14. Can J & J keep the magic going? Taylor A Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959 [No Abstract] [Full Text] [Related]
15. Extensive consolidations continue in drug industry. Scott L Mod Healthc; 1994 Sep; 24(36):12. PubMed ID: 10136392 [No Abstract] [Full Text] [Related]
16. Keys to CRM success. How well are contract pharmaceutical companies doing in the CRM game? Kros JF; Molis J Mark Health Serv; 2004; 24(4):32-6. PubMed ID: 15612224 [No Abstract] [Full Text] [Related]
17. Deal watch: Bristol-Myers Squibb and Exelixis collaborate on kinase inhibitors. Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180098 [No Abstract] [Full Text] [Related]
18. A very firm handshake: biotech's growing negotiating power. Thiel KA Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058 [No Abstract] [Full Text] [Related]
19. Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain. James JS AIDS Treat News; 2001 Feb; (361):5-7. PubMed ID: 12765151 [TBL] [Abstract][Full Text] [Related]